Cargando…
Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action
CD73 (ecto-5′-nucleotidase) has recently been established as a promising immuno-oncology target. Given its role in activating purinergic signaling pathways to elicit immune suppression, antagonizing CD73 (i.e., releasing the brake) offers a complimentary pathway to inducing anti-tumor immune respons...
Autores principales: | Geoghegan, James C., Diedrich, Gundo, Lu, Xiaojun, Rosenthal, Kim, Sachsenmeier, Kris F., Wu, Herren, Dall'Acqua, William F., Damschroder, Melissa M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037986/ https://www.ncbi.nlm.nih.gov/pubmed/26854859 http://dx.doi.org/10.1080/19420862.2016.1143182 |
Ejemplares similares
-
Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence
por: Mazor, Yariv, et al.
Publicado: (2017) -
Molecular basis for the mechanism of action of an anti-TACE antibody
por: Peng, Li, et al.
Publicado: (2016) -
Bi-Epitope SPR Surfaces: A Solution to Develop Robust Immunoassays
por: Peng, Li, et al.
Publicado: (2014) -
Targeting CD73 in the tumor microenvironment with MEDI9447
por: Hay, Carl M., et al.
Publicado: (2016) -
Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody
por: Peng, Li, et al.
Publicado: (2015)